Vanguard Group Inc Impel Pharmaceuticals Inc Transaction History

Vanguard Group Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.31 - $1.75 $819 - $4,628	-2,645 Reduced 0.52%	505,231 $217,000
Q2 2023 Aug 14, 2023	SELL	$1.08 - $2.75 $6,689 - $17,033	-6,194 Reduced 1.2%	507,876 $645,000
Q4 2022 Feb 10, 2023	BUY	$2.59 - $4.0 $523 - $808	202 Added 0.04%	514,070 $1.93 Million
Q2 2022 Aug 12, 2022	SELL	$5.83 - $10.12 $104,450 - $181,309	-17,916 Reduced 3.37%	513,868 $4.79 Million
Q1 2022 May 13, 2022	BUY	$5.86 - $9.85 $234,587 - $394,315	40,032 Added 8.14%	531,784 $3.39 Million
Q4 2021 Feb 14, 2022	BUY	$8.33 - $12.14 $1.06 Million - $1.54 Million	127,211 Added 34.9%	491,752 $4.24 Million
Q3 2021 Nov 12, 2021	BUY	$8.38 - $26.13 $1.52 Million - $4.72 Million	180,788 Added 98.39%	364,541 $4.44 Million
Q2 2021 Aug 13, 2021	BUY	$7.33 - $15.2 $1.35 Million - $2.79 Million	183,753 New	183,753 $1.63 Million

Ticker IMPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,738,800
Market Cap $475K
Description
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The c...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.